Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 206
- Registration Number
- NCT00697450
- Locations
- 🇨🇿
Novo Nordisk Investigational Site, Prague, Czech Republic
Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24975
- Registration Number
- NCT00696163
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2188
- Registration Number
- NCT00687284
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Kosice, Slovakia
Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10008
- Registration Number
- NCT00687063
Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 19
- Registration Number
- NCT00676819
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Köln, Germany
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3809
- Registration Number
- NCT00676741
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Delivery Systems
- Interventions
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT00675220
- Locations
- 🇵🇭
Novo Nordisk Investigational Site, Manilla, Philippines
Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 942
- Registration Number
- NCT00675493
Observational Study of Patients With Diabetes Using Levemir® FlexPen®
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 797
- Registration Number
- NCT00670683
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6500
- Registration Number
- NCT00670722
- Locations
- 🇨🇿
Novo Nordisk Investigational Site, Prague, Czech Republic
© Copyright 2025. All Rights Reserved by MedPath